Airway remodeling and long-term decline in lung function in asthma

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 1, 2003, Pages 9-14

  Ten Hacken, Nick H T ^a   Postma, Dirkje S ^a   Timens, Wim ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 13;

AIRWAY OBSTRUCTION; ASTHMA; DEGRANULATION; EPITHELIUM; FIBROSIS; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LUNG FUNCTION; LUNG PARENCHYMA; MAST CELL; REVIEW; SMOKING; SMOOTH MUSCLE FIBER; VIRUS INFECTION;

AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHITIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RESPIRATORY MUCOSA; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATUS ASTHMATICUS;

EID: 0037212774     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200301000-00002     Document Type: Review

References (57)

1. Martinez FD, Wright AL, Taussig LM, et al.: Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995, 332:133-138.
2. Sears MR: Consequences of long-term inflammation. The natural history of asthma. Clin Chest Med 2000, 21:315-329.
3. Weiss ST, Tosteson TD, Segal MR, et al.: Effects of asthma on pulmonary function in children. A longitudinal population-based study. Am Rev Respir Dis 1992, 145:58-64.
4. Roorda RJ, Gerritsen J., van Aalderen WM, et al.: Follow-up of asthma from childhood to adulthood: influence of potential childhood risk factors on the outcome of pulmonary function and bronchial responsiveness in adulthood. J Allergy Clin Immunol 1994, 93:575-584.
5. Lange P, Parner J, Vestbo J, et al.: A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998, 339:1194-1200.
6. Ulrik CS, Backer V: Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999, 14:892-896.
7. Brown PJ, Greville HW, Finucane KE: Asthma and irreversible airflow obstruction. Thorax 1984, 39:131-136.
8. Hudon C, Turcotte H, Laviolette M, et al.: Characteristics of bronchial asthma with incomplete reversibility of airflow obstruction. Ann Allergy Asthma Immunol 1997, 78:195-202.
9. Panhuysen CIM, Schouten JP, Koëter GH et al: Risk factors for the development of irreversible airway obstruction in asthma patients: a 25 year follow-up study. In Genetics and Natural History of Asthma. Thesis. Groningen 1996:133-147.
10. Grol MH, Gerritsen J, Vonk JM, et al.: Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years. A 30-year follow up study. Am J Respir Crit Care Med 1999, 160:1830-1837.
11. Forastiere F, Corbo GM, Dell'Orco V, et al.: A longitudinal evaluation of bronchial responsiveness to methacholine in children: Role of baseline lung function, gender, and change in atopic status. Am J Respir Crit Care Med 1996, 153:1098-1104.
12. Martin AJ, Landau LI, Phelan PD: Lung function in young adults who had asthma in childhood. Am Rev Respir Dis 1980, 122:609-616.
13. Redline S, Tager IB, Segal MR, et al.: The relation between longitudinal change in pulmonary function and nonspecific airway responsiveness in children and young adults. Am Rev Respir Dis 1989, 140:179-184.
14. Sherrill D, Sears MR, Lebowitz MD, et al.: The effects of airway hyperresponsiveness, wheezing, and atopy on longitudinal pulmonary function in children: A 6-year follow-up study. Pediatr Pulmonol 1992, 13:78-85.
15. Palmer LJ, Rye PJ, Gibson NA, et al.: Airway responsiveness in early infancy predicts asthma, lung function, and respiratory symptoms by school age. Am J Respir Crit Care Med 2001, 163:37-42. This study shows for the first time that before many environmental influences occur, hyperresponsiveness is already present just after birth and determines the level of lung function 6 year later.
16. Haahtela T, Jarvinen M, Kava T, et al.: Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994, 331:700-705.
17. Ulrik CS: Outcome of asthma: Longitudinal changes in lung function. Eur Respir J 1999, 13:904-918.
18. Little SA, MacLeod KJ, Chalmers GW, et al.: Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma. Am J Med 2002, 112:446-452.
19. Redington AE: Fibrosis and airway remodeling. Clin Exp Allergy 2000, 30(suppl 1):42-45.
20. Tulic MK, Christodoulopoulos P, Hamid Q: Small airway inflammation in asthma. Respir Res 2001, 2:333-339. This review expertly addresses the role of small airway disease in asthma.
21. Hogg JC: Role of latent viral infections in chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2001, 164(10 Pt 2):S71-S75.
22. Schwarze J, Gelfand EW: Respiratory viral infections as promoters of allergic sensitization and asthma in animal models. Eur Respir J 2002, 19:341-349.
23. von HL: Role of persistent infection in the control and severity of asthma: Focus on Chlamydia pneumoniae. Eur Respir J 2002, 19:546-556.
24. ten Brinke A, van Dissel JT, Sterk PJ, et al.: Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection. J Allergy Clin Immunol 2001, 107:449-454.
25. Chalmers GW, MacLeod KJ, Thomson L, et al.: Smoking and airway inflammation in patients with mild asthma. Chest 2001, 120:1917-1922.
26. Chalmers GW, MacLeod KJ, Little SA, et al.: Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002, 57:226-230. The first prospective study measuring an adverse effect of smoking on the generally occurring positive steroid response in asthma: smoking affects asthmatics and not only chronic obstructive pulmonary disease.
27. Pedersen B, Dahl R, Karlstrom R, et al.: Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med 1996, 153:1519-1529.
28. Kerstjens HA, Brand PL, Postma DS: Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 154(6 Pt 2):S266-S272.
29. Lee YC, Lee HB, Rhee YK, et al.: The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma. Clin Exp Allergy 2001, 31:1623-1630. This study evaluated MMP-9 levels in sputum during and after spontaneous attacks of asthma. Pro-MMP-9 activities and MMP-9 concentrations in asthmatic patients significantly exceeded those of control subjects. The activities of pro-MMP-9 were significantly higher in acute asthmatic patients than in stable asthmatic patients. The elevated MMP- 9 activities significantly decreased after 7 and 28 days of therapy.
30. Kumar RK, Herbert C, Yang M, et al.: Role of interleukin-13 in eosinophil accumulation and airway remodeling in a mouse model of chronic asthma. Clin Exp Allergy 2002, 32:1104-1111.
31. Sakai K, Yokoyama A, Kohno N, et al.: Prolonged antigen exposure ameliorates airway inflammation but not remodeling in a mouse model of bronchial asthma. Int Arch Allergy Immunol 2001, 126:126-134.
32. Richter A, Puddicombe SM, Lordan JL, et al.: The contribution of interleukin (IL)-4 and IL·13 to the epithelial- mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 2001, 25:385-391. In vitro study on the profibrogenic effects of IL-4 and IL-13 using bronchial fibroblasts from asthmatic subjects. The authors ultimately concluded that epithelial activation by IL-13 or IL-4 plays a critical role in initiating remodeling through release of TGF·beta2. TGF-β2 then activates the underlying myofibroblasts to secrete matrix proteins and smooth muscle and vascular mitogens to propagate remodeling changes into the submucosa.
33. Kraft M, Lewis C, Pham D, Chu HW: IL-4, IL-13, and dexamethasone augment fibroblast proliferation in asthma. J Allergy Clin Immunol 2001, 107:602-606.
34. Page S, Ammit AJ, Black JL Armour CL: Human mast cell and airway smooth muscle cell interactions: Implications for asthma. Am J Physiol Lung Cell Mol Physiol 2001, 281:L1313-L1323.
35. Sommerhoff CP: Mast cell tryptases and airway remodeling. Am J Respir Crit Care Med 2001, 164(10 Pt 2):S52-S58.
36. Ammit AJ, Bekir SS, Johnson PR, et al.: Mast cell numbers are increased in the smooth muscle of human sensitized isolated bronchi. Am J Respir Crit Care Med 1997, 155:1123-1129.
37. Berger P, Walls AF, Marthan R, et al.: Immunoglobulin E·induced passive sensitization of human airways: An immunohistochemical study. Am J Respir Crit Care Med 1998, 157:610-616.
38. Brightling CE, Bradding P, Symon FA, et al.: Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002, 346:1699-1705. Immunohistochemical analysis of bronchial biopsies from subjects with asthma, eosinophilic bronchitis, and healthy controls. The number of tryptase-positive mast cells in airway smooth muscle from subjects with asthma was substantially higher than that in subjects with eosinophilic bronchitis and that in normal controls, whereas T cells and eosinophils were not usually seen in airway smooth muscle in any of the groups.
39. Lazaar AL, Plotnick MI, Kucich U et al.: Mast cell chymase modifies cell-matrix interactions and inhibits mitogen-induced proliferation of human airway smooth muscle cells. J Immunol 2002, 169:1014-1020.
40. Berger P, Perng DW, Thabrew H, et al.: Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. J Appl Physiol 2001, 91:1372-1379.
41. Martin RJ, Cicutto LC, Smith HR, et al.: Airways inflammation in nocturnal asthma. Am Rev Respir Dis 1991, 143:351-357.
42. Wenzel SE, Szefler SJ, Leung DY, et al.: Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997, 156(3 Pt 1):737-743.
43. Holgate ST (EMFUMOSA): Clinical characteristics associated to severe asthma. Am.J Respir.Crit Care Med. 159, A700. 1999. Ref Type: Abstract
44. Gibson PG, Simpson JL, Saltos N: Heterogeneity of airway inflammation in persistent asthma: Evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001, 119:1329-1336.
45. Woodruff PG, Khashayar R, Lazarus SC, et al.: Relation between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001, 108:753-758.
46. Douwes J, Gibson P, Pekkanen J, Pearce N: Non-eosinophilic asthma: Importance and possible mechanisms. Thorax 2002, 57:643-648. Outstanding review summarizing the increasing evidence indicating that inflammatory mechanisms other than eosinophilic inflammation may be involved in the pathophysiology of asthma. As noneosinophilic airway inflammation occurs rather frequently in asthma, the authors speculate that this may have major consequences for treatment, prevention, and research.
47. Holgate ST, Davies DE, Lackie PM, et al.: Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000, 105(2 Pt 1):193-204.
48. Ordonez CL, Khashayar R, Wong HH, et al.: Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med 2001, 163:517-523. Study on the underlying pathology of mucus production in asthma using bronchial biopsies and induced sputum. Even mild asthma was associated with goblet cell hyperplasia and increased stored mucin in the airway epithelium, whereas moderate asthma was associated with increased stored mucin and secreted mucin. The authors suggested that chronic degranulation of goblet cells may contribute to chronic airway narrowing in moderate asthma.
49. Holgate ST: Epithelial damage and response. Clin Exp Allergy 2000, 30(suppl 1):37-41.
50. Takeyama K, Fahy JV, Nadel JA: Relation of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med 2001, 163:511-516.
51. Puddicombe SM, Polosa R, Richter A, et al.: Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J 2000, 14:1362-1374.
52. Burgel PR, Lazarus SC, Tam DC, et al.: Human eosinophils induce mucin production in airway epithelial cells via epidermal growth factor receptor activation. J Immunol 2001, 167:5948-5954.
53. Lordan JL, Bucchieri F, Richter A, et al.: Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells. J Immunol 2002, 169:407-414.
54. Pulleyn LJ, Newton R, Adcock IM, et al.: TGFbeta 1 allele association with asthma severity. Hum Genet 2001, 109:623-627. TGF is a multifunctional cytokine involved in pro- and antiinflammatory pathways. It is implicated in fibrosis. Interestingly, the C-509T variant in the promoter region is associated with more severe asthma.
55. Xu J, Benyon RC, Leir SH, et al.: Matrix metalloproteinase-2 from bronchial epithelial cells induces the proliferation of subepithelial fibroblasts. Clin Exp Allergy 2002, 32:881-888.
56. Gelb AF, Licuanan J, Shinar CM, et al.: Unsuspected loss of lung elastic recoil in chronic persistent asthma. Chest 2002, 121:715-721.
57. Gelb AF, Zamel N: Lung elastic recoil in acute and chronic asthma. Curr Opin Pulm Med 2002, 8:50-53.